In ACE-CL-311, an ongoing, randomized, open-label phase 3 study with a target enrollment of 780 patients with treatment-naïve CLL without del(17p) or mutated TP53, acalabrutinib in combination with the BCL-2 inhibitor venetoclax with and without obinutuzumab versus chemotherapy will be evaluated (expected completion in 2024) (67). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.